A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases

Summary

This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases. Patients will receive RO5185426 at a dose of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs.

Timeline

Start

2010-11-22

Primary completion

2012-03-14

Completion

2012-03-14

Drugs

Indications